• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CDY
Click for more information
1.43% 7.1¢

CELLMID LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CDYTrading HaltPRICE SENSITIVE23/04/12
CDYFinal Share Issue to La Jolla Cove - Appendix 3B20/04/12
CDYCommercial website launched for Evolis19/04/12
CDYUSA Antibody Patent for Adhesion AllowedPRICE SENSITIVE18/04/12
CDYAppendix 3B16/04/12
CDYResponse to ASX Query05/04/12
CDYAppendix 3B04/04/12
CDYChange of Director's Interest Notice03/04/12
CDYAppendix 3B29/03/12
CDYMedia Launch of Evolis Hair ProductsPRICE SENSITIVE29/03/12
CDYAppendix 3B16/03/12
CDYChange of Director's Interest Notice13/03/12
CDYAppendix 3B12/03/12
CDYAppendix 3B06/03/12
CDYAnnual Report on Celera (Quest) LicensePRICE SENSITIVE05/03/12
CDYAppendix 4D and Half Year AccountsPRICE SENSITIVE28/02/12
CDYAppendix 3B28/02/12
CDYAppendix 3B20/02/12
CDYNotice of change of interests of substantial holder20/02/12
CDYTGA Registration and Launch of Cellmid's Evolis ProductsPRICE SENSITIVE15/02/12
CDYLa Jolla Cove Funding Agreement TerminatedPRICE SENSITIVE13/02/12
CDYAppendix 4C - quarterlyPRICE SENSITIVE30/01/12
CDYAppendix 3B24/01/12
CDYAppendix 3B16/12/11
CDYBecoming a substantial holder08/12/11
CDYChange of Director's Interest Notice08/12/11
CDYChange of Director's Interest Notice08/12/11
CDYChange of Director's Interest Notice08/12/11
CDYChange of Director's Interest Notice08/12/11
CDYChange of Director's Interest Notice08/12/11
CDYDispatch of Rights Issue Holdings Statements02/12/11
CDYCompleted Midkine Study for Normal Reference RangePRICE SENSITIVE01/12/11
CDYRights Issue and Placement of ShortfallPRICE SENSITIVE29/11/11
CDYAmended Constitution25/11/11
CDYResults of Meeting25/11/11
CDYClarification Rights Issue Closing Date24/11/11
CDYRights Issue Extended until 30 November 201124/11/11
CDYUS Patent for the Prevention or Treatment of IschemiaPRICE SENSITIVE14/11/11
CDYNon-Renounceable Rights Issue Despatch of Offer Document09/11/11
CDYAppendix 4C - quarterlyPRICE SENSITIVE31/10/11
CDYPro Forma Appendix 3B27/10/11
CDYAnnual Report to Shareholders26/10/11
CDYNotice of Annual General Meeting / Proxy Form26/10/11
CDYNon-Renounceable Rights IssuePRICE SENSITIVE26/10/11
CDYAmended Constitution of November 200820/10/11
CDYCE Marking of Cellmid's Midkine ELISAPRICE SENSITIVE12/10/11
CDYCompleted Humanisation of First Ever Anti-midkine AntibodyPRICE SENSITIVE06/10/11
CDYResults of Meeting30/09/11
CDYEGM Presentation by the CEO30/09/11
CDYNotice of Extraordinary General Meeting/Proxy Form31/08/11
CDYAppendix 4E and Preliminary Final ReportPRICE SENSITIVE29/08/11
CDYChange of Director's Interest Notice17/08/11
CDYCompleted GMP Manufacture of Midkine TestPRICE SENSITIVE02/08/11
CDYAppendix 4C - quarterlyPRICE SENSITIVE25/07/11
CDYAppendix 3B10/06/11
CDYChange of Director's Interest Notice31/05/11
CDYChange of Director's Interest Notice30/05/11
CDYCelera License UpdatePRICE SENSITIVE25/05/11
CDYAppendix 4C - quarterlyPRICE SENSITIVE19/04/11
CDYAppendix 3B14/04/11
CDYAppendix 3B14/04/11
CDYCellmid Signs Antibody Humanisation CollaborationPRICE SENSITIVE13/04/11
CDYCompletion of Proof of Concept Study for Heart AttackPRICE SENSITIVE11/04/11
CDYAppendix 3B06/04/11
CDYUpdate on Cellmid's Japanese OperationsPRICE SENSITIVE16/03/11
CDYChange of Director's Interest Notice15/03/11
CDYChange of Director's Interest Notice07/03/11
CDYCellmid News22/02/11
CDYAppendix 4D and Half Year AccountsPRICE SENSITIVE22/02/11
CDYAppendix 3B02/02/11
CDYAppendix 3B10/01/11
CDYCellmid Share Trading Policy05/01/11
CDYResignation of Director10/12/10
CDYCellmid Launches New Hair Loss Products08/12/10
CDYAppendix 3B16/11/10
CDYChange of Director's Interest Notice15/11/10
CDYMidkine Conference Results10/11/10
CDYResults of the Annual General Meeting of Members03/11/10
CDYAGM Presentation03/11/10
CDYCellmid Launches Midkine Blood TestPRICE SENSITIVE03/11/10
CDYFirst Quarter Activities ReportPRICE SENSITIVE28/10/10
CDYCellmid Launches Lifestyle Subsidiary27/10/10
CDYChange of Company Secretary06/10/10
CDYAnnual Report to shareholders01/10/10
CDYNotice of Annual General Meeting/Proxy Form01/10/10
CDYCellmid Secures US$8M FundingPRICE SENSITIVE15/09/10
CDYPreliminary Final ReportPRICE SENSITIVE27/08/10
CDYPreclinical Study Shows Reduction in Disease SeverityPRICE SENSITIVE19/08/10
CDYAppendix 3B30/07/10
CDYAppendix 4C - quarterlyPRICE SENSITIVE28/07/10
CDYAppendix 3B09/07/10
CDYCellmid and Pacific Edge Sign Cancer Diagnostic LicensePRICE SENSITIVE19/05/10
CDYJoint Research Agreement Signed with Kumamoto UniversityPRICE SENSITIVE21/04/10
CDYAppendix 4C - quarterlyPRICE SENSITIVE21/04/10
CDYNew midkine results for heart attack treatmentPRICE SENSITIVE12/04/10
CDYValidated Cancer Marker Presentation19/03/10
CDYCDY Signs Collaboration for Heart Attack TreatmentPRICE SENSITIVE03/03/10
CDYCellmid News25/02/10
CDYHalf Yearly Report and AccountsPRICE SENSITIVE25/02/10
CDYAppendix 3B19/02/10
CDYTrading Halt
23/04/12PRICE SENSITIVE
CDYFinal Share Issue to La Jolla Cove - Appendix 3B
20/04/12
CDYCommercial website launched for Evolis
19/04/12
CDYUSA Antibody Patent for Adhesion Allowed
18/04/12PRICE SENSITIVE
CDYAppendix 3B
16/04/12
CDYResponse to ASX Query
05/04/12
CDYAppendix 3B
04/04/12
CDYChange of Director's Interest Notice
03/04/12
CDYAppendix 3B
29/03/12
CDYMedia Launch of Evolis Hair Products
29/03/12PRICE SENSITIVE
CDYAppendix 3B
16/03/12
CDYChange of Director's Interest Notice
13/03/12
CDYAppendix 3B
12/03/12
CDYAppendix 3B
06/03/12
CDYAnnual Report on Celera (Quest) License
05/03/12PRICE SENSITIVE
CDYAppendix 4D and Half Year Accounts
28/02/12PRICE SENSITIVE
CDYAppendix 3B
28/02/12
CDYAppendix 3B
20/02/12
CDYNotice of change of interests of substantial holder
20/02/12
CDYTGA Registration and Launch of Cellmid's Evolis Products
15/02/12PRICE SENSITIVE
CDYLa Jolla Cove Funding Agreement Terminated
13/02/12PRICE SENSITIVE
CDYAppendix 4C - quarterly
30/01/12PRICE SENSITIVE
CDYAppendix 3B
24/01/12
CDYAppendix 3B
16/12/11
CDYBecoming a substantial holder
08/12/11
CDYChange of Director's Interest Notice
08/12/11
CDYChange of Director's Interest Notice
08/12/11
CDYChange of Director's Interest Notice
08/12/11
CDYChange of Director's Interest Notice
08/12/11
CDYChange of Director's Interest Notice
08/12/11
CDYDispatch of Rights Issue Holdings Statements
02/12/11
CDYCompleted Midkine Study for Normal Reference Range
01/12/11PRICE SENSITIVE
CDYRights Issue and Placement of Shortfall
29/11/11PRICE SENSITIVE
CDYAmended Constitution
25/11/11
CDYResults of Meeting
25/11/11
CDYClarification Rights Issue Closing Date
24/11/11
CDYRights Issue Extended until 30 November 2011
24/11/11
CDYUS Patent for the Prevention or Treatment of Ischemia
14/11/11PRICE SENSITIVE
CDYNon-Renounceable Rights Issue Despatch of Offer Document
09/11/11
CDYAppendix 4C - quarterly
31/10/11PRICE SENSITIVE
CDYPro Forma Appendix 3B
27/10/11
CDYAnnual Report to Shareholders
26/10/11
CDYNotice of Annual General Meeting / Proxy Form
26/10/11
CDYNon-Renounceable Rights Issue
26/10/11PRICE SENSITIVE
CDYAmended Constitution of November 2008
20/10/11
CDYCE Marking of Cellmid's Midkine ELISA
12/10/11PRICE SENSITIVE
CDYCompleted Humanisation of First Ever Anti-midkine Antibody
06/10/11PRICE SENSITIVE
CDYResults of Meeting
30/09/11
CDYEGM Presentation by the CEO
30/09/11
CDYNotice of Extraordinary General Meeting/Proxy Form
31/08/11
CDYAppendix 4E and Preliminary Final Report
29/08/11PRICE SENSITIVE
CDYChange of Director's Interest Notice
17/08/11
CDYCompleted GMP Manufacture of Midkine Test
02/08/11PRICE SENSITIVE
CDYAppendix 4C - quarterly
25/07/11PRICE SENSITIVE
CDYAppendix 3B
10/06/11
CDYChange of Director's Interest Notice
31/05/11
CDYChange of Director's Interest Notice
30/05/11
CDYCelera License Update
25/05/11PRICE SENSITIVE
CDYAppendix 4C - quarterly
19/04/11PRICE SENSITIVE
CDYAppendix 3B
14/04/11
CDYAppendix 3B
14/04/11
CDYCellmid Signs Antibody Humanisation Collaboration
13/04/11PRICE SENSITIVE
CDYCompletion of Proof of Concept Study for Heart Attack
11/04/11PRICE SENSITIVE
CDYAppendix 3B
06/04/11
CDYUpdate on Cellmid's Japanese Operations
16/03/11PRICE SENSITIVE
CDYChange of Director's Interest Notice
15/03/11
CDYChange of Director's Interest Notice
07/03/11
CDYCellmid News
22/02/11
CDYAppendix 4D and Half Year Accounts
22/02/11PRICE SENSITIVE
CDYAppendix 3B
02/02/11
CDYAppendix 3B
10/01/11
CDYCellmid Share Trading Policy
05/01/11
CDYResignation of Director
10/12/10
CDYCellmid Launches New Hair Loss Products
08/12/10
CDYAppendix 3B
16/11/10
CDYChange of Director's Interest Notice
15/11/10
CDYMidkine Conference Results
10/11/10
CDYResults of the Annual General Meeting of Members
03/11/10
CDYAGM Presentation
03/11/10
CDYCellmid Launches Midkine Blood Test
03/11/10PRICE SENSITIVE
CDYFirst Quarter Activities Report
28/10/10PRICE SENSITIVE
CDYCellmid Launches Lifestyle Subsidiary
27/10/10
CDYChange of Company Secretary
06/10/10
CDYAnnual Report to shareholders
01/10/10
CDYNotice of Annual General Meeting/Proxy Form
01/10/10
CDYCellmid Secures US$8M Funding
15/09/10PRICE SENSITIVE
CDYPreliminary Final Report
27/08/10PRICE SENSITIVE
CDYPreclinical Study Shows Reduction in Disease Severity
19/08/10PRICE SENSITIVE
CDYAppendix 3B
30/07/10
CDYAppendix 4C - quarterly
28/07/10PRICE SENSITIVE
CDYAppendix 3B
09/07/10
CDYCellmid and Pacific Edge Sign Cancer Diagnostic License
19/05/10PRICE SENSITIVE
CDYJoint Research Agreement Signed with Kumamoto University
21/04/10PRICE SENSITIVE
CDYAppendix 4C - quarterly
21/04/10PRICE SENSITIVE
CDYNew midkine results for heart attack treatment
12/04/10PRICE SENSITIVE
CDYValidated Cancer Marker Presentation
19/03/10
CDYCDY Signs Collaboration for Heart Attack Treatment
03/03/10PRICE SENSITIVE
CDYCellmid News
25/02/10
CDYHalf Yearly Report and Accounts
25/02/10PRICE SENSITIVE
CDYAppendix 3B
19/02/10
refresh Created with Sketch. REFRESH
 

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Parkes Au-Cu project to 'transform' Adavale Resources with key targets Adavale Resources Ltd has entered into an all-scrip acquisition of the Parkes gold and copper project in New South Wales
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher Vitrafy Life Sciences Limited (ASX:VFY) has defied this month’s odds to become the only newly-listed Australian company to survive a surprisingly rough November (for newcomers, at least) without sagging below its IPO price.The cryopreservation biotech did give some back on Friday,...
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.